NCT04802811View on ClinicalTrials.gov

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

November 10, 2021

Study Completion Date

November 10, 2021

Conditions

HIV-1 Infection

Interventions

DRUG

SHR2150；Placebo

Single dose；SHR2150-dose 1 or Placebo-dose 1

DRUG

SHR2150；Placebo

Single dose；SHR2150-dose 2 or Placebo-dose 2

DRUG

SHR2150；Placebo

Single dose；SHR2150-dose 3 or Placebo-dose 3

DRUG

SHR2150；Placebo

Single dose；SHR2150-dose 4 or Placebo-dose 4

DRUG

SHR2150；Placebo

Single dose；SHR2150-dose 5 or Placebo-dose 5

Trial Locations (1)

10069

Beijing youan Hospital,Capital medical university, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04802811 - A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects | Biotech Hunter | Biotech Hunter